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Introduction
Systemic sclerosis (SSc) is characterized by the excessive
deposition of collagen and other connective tissue
components in skin and multiple internal organs,
prominent and often severe alterations in the microvas-
culature, and humoral and cellular immunologic
abnormalities (for reviews see refs. 1–4). The exact
mechanisms involved in the pathogenesis of SSc are
not known. However, it is clear that progressive cuta-
neous, visceral, and vascular fibrosis is responsible for
most of its clinical manifestations (4, 5). Indeed, SSc
severity and mortality are determined by the extent and
progression of tissue fibrosis (6).
Despite recent advances in understanding the regu-
lation of collagen gene expression, the mechanisms
responsible for the pathologic increase in the expres-
sion of collagen genes in SSc have not been elucidated.
Fibroblasts from affected SSc skin cultured in vitro
produce excessive amounts of various collagens (4, 7,
8), and display increased transcription of the corre-
sponding genes (9, 10). However, the mechanisms
responsible for the increased transcriptional activity of
collagen genes in SSc fibroblasts are not fully under-
stood. TGF-β plays a crucial role in the development of
tissue fibrosis (reviewed in refs. 11, 12), and a plausible
hypothesis has suggested its involvement in the patho-
genesis of SSc (13). The numerous activities of this
pleiotropic factor have made it difficult to elucidate the
exact mechanisms by which it exerts its fibrogenic
effects, although it has been demonstrated that the
intracellular pathways involved are mediated through
complex interactions between specific cell-surface
receptors and several intracellular proteins of the Smad
family (reviewed in refs. 14, 15).
We recently examined other intracellular signaling
constituents through which TGF-β may upregulate the
expression of matrix protein genes, and identified phos-
phatidylcholine-specific phospholipase C, protein kinase
C-δ (PKC-δ), geranylgeranyl transferase I, and p38 as pos-
sible participants (16–18). These findings suggested that
one or more of these proteins could also be involved in
the upregulation of collagen gene expression in SSc.
Indeed, we recently demonstrated that inhibition of ger-
anylgeranyl transferase I caused a profound and selective
inhibition of expression of type I and type III collagen
genes in normal and SSc dermal fibroblasts (19).
Here, we examined the effects of rottlerin, a specific
inhibitor of PKC-δ (20, 21), on the expression of type I
and type III collagen genes (COL1A1 and COL3A1,
respectively) in normal and SSc dermal fibroblasts in
vitro. Rottlerin inhibited COL1A1 and COL1A3 expres-
sion in a dose-dependent manner in both cell types,
without affecting the expression of other genes exam-
ined. The inhibitory effects of rottlerin on COL1A1
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Working with cultured dermal fibroblasts derived from control individuals and patients with sys-
temic sclerosis (SSc), we have examined the effects of protein kinase C-δ (PKC-δ) on type I collagen
biosynthesis and steady-state levels of COL1A1 and COL3A1 mRNAs. Rottlerin, a specific inhibitor
of PKC-δ, exerted a powerful, dose-dependent inhibition of type I and type III collagen gene expres-
sion in normal and SSc cells. Optimal rottlerin concentrations caused a 70–90% inhibition of type I
collagen production, a >80% reduction in COL1A1 mRNA, and a >70% reduction in COL3A1 mRNA
in both cell types. In vitro nuclear transcription assays and transient transfections with COL1A1 pro-
moter deletion constructs demonstrated that rottlerin profoundly reduced COL1A1 transcription
and that this effect required a 129-bp promoter region encompassing nucleotides –804 to –675. This
COL1A1 segment imparted rottlerin sensitivity to a heterologous promoter. Cotransfections of
COL1A1 promoter constructs with a dominant-negative PKC-δ expression plasmid showed that sup-
pression of this kinase silenced COL1A1 promoter activity. The results indicate that PKC-δ partici-
pates in the upregulation of collagen gene transcription in SSc and suggest that treatment with 
PKC-δ inhibitors could suppress fibrosis in this disease.
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expression resulted from a profound reduction in
COL1A1 transcription that was exerted through a 129-
bp region of the gene promoter. Studies to examine the
possibility that PKC-δ is involved in the pathogenesis of
the upregulated collagen gene expression in SSc showed
that SSc cells displayed higher levels of immunoreactive
protein when examined by immunofluorescence and
Western analysis. Furthermore, cotransfection of SSc
cells with COL1A1 promoter constructs and a domi-
nant-negative PKC-δ expression construct showed a
reduction of COL1A1 promoter activity. These results
indicate that PKC-δ may be involved in the upregulated
expression of interstitial collagen genes in SSc, and sug-
gest that specific inhibitors of this enzyme should be
further investigated as potential therapeutic approach-
es for this devastating and incurable disease.
Methods
Fibroblast cultures. Dermal fibroblast cell lines were estab-
lished from patients with SSc who fulfilled the Ameri-
can College of Rheumatology criteria for the classifica-
tion of SSc (22). To avoid variability introduced by
heterogeneity in the clinical characteristics and the stage
of evolution of SSc, only cells from untreated patients
with diffuse SSc of recent onset and rapid progression
were studied, as described previously (8, 10, 19). The cell
lines were obtained from full-thickness skin biopsies
surgically excised for diagnostic purposes from the lead-
ing edge of clinically apparent SSc lesions. Normal
fibroblasts were obtained from age- and sex-matched
individuals undergoing surgical procedures. All studies
were approved by the Institutional Review Board of
Thomas Jefferson University. Fibroblast cultures were
established as described previously (8, 10, 19), and were
cultured in DMEM supplemented with 10% FBS in 5%
CO2 for 4 days until they reached confluence.
For all studies, only early passage (<12) fibroblasts were
used to avoid changes in their original phenotype dur-
ing subculture. Cells were maintained in DMEM con-
taining 10% FBS (Life Technologies Inc., Grand Island,
New York, USA), 1% vitamins, 2 mM glutamine, antibi-
otics, and Fungizone, and were incubated at 37°C in a
5% CO2 humidified atmosphere. The cultures were sup-
plemented with 50 µg/ml ascorbic acid for 24 hours to
optimize their level of collagen production. At the con-
clusion of all experiments, the cells were counted and
their viability was assessed using trypan blue exclusion.
High-resolution fluorescence immunomicroscopy. Fibrob-
lasts (40,000) were plated on coverslips and maintained
in 10% FBS in DMEM for 24 hours. When the cells
reached confluence, they were prepared for analysis
with high-resolution fluorescence immunomicroscopy.
Cells were washed in PBS and fixed in 2 ml of freshly
prepared 3% paraformaldehyde for 10 minutes. After
the fixative was washed off with PBS, the cells were per-
meabilized with 0.05% Triton X-100 in PBS. Nonspecif-
ic binding was blocked with 4% normal goat serum in
PBS with 0.5% Triton X-100. The cells were incubated
for 30 minutes with anti–PKC-δ antibodies at a 1:10
dilution. After washing off the primary antibody, a
1:100 dilution of fluorescein-conjugated goat anti-rab-
bit IgG (Vector Laboratories Inc., Burlingame, Califor-
nia, USA) was added to the coverslips; after 30 minutes
these were mounted on slides using the SlowFade Light
Antifade Kit from Molecular Probes Inc. (Eugene, Ore-
gon, USA). All staining steps were carried out at 37°C.
Fluorescence was visualized using excitation filters at
450–490 nM and emission filters at 500–550 nM with a
495 LP dichroic filter (Chroma Technology Corp., Brat-
tleboro, Vermont, USA). IPLab scientific imaging soft-
ware (Scanalytics Inc., Fairfax, Virginia, USA) was used
for image and acquisition analysis.
Western analysis of PKC-δ in cell lysates. To examine the
amounts of immunoreactive PKC-δ in cell lysates, 100-ml
dishes of confluent normal and SSc cells were washed
three times with 25 ml of cold PBS; subsequently the
monolayers were lysed in 250 µl of lysis buffer (10 mM
Tris-HCl at pH 7.25, 1 mM MgCl2, 0.2% Triton X-100)
containing protease inhibitors and 1 mM PMSF. The sus-
pension was sonicated and then centrifuged at 11,000 g
for 10 minutes at 4°C. Aliquots containing 80 µg of lysate
were boiled for 10 minutes and electrophoresed on 7.5%
polyacrylamide gels (Bio-Rad Laboratories Inc., Hercules,
California, USA) at 200 V for 1 hour. Following elec-
trophoresis, the blots were transferred to an ULTRAN
membrane (Schleicher and Schuell, Dassel, Germany),
blocked for 2 hours with 5% powdered milk dissolved in
PBS and 0.1% Tween 20, and then incubated overnight at
4°C with 4 µg/ml of a rabbit polyclonal IgG anti–PKC-δ
antibody (Upstate Biotechnology Inc., Lake Placid, New
York, USA). The immunoreactive proteins were visualized
using a goat anti-rabbit secondary antibody conjugated
to horseradish peroxidase using the ECL chemilumines-
cence detection system (Amersham Pharmacia Biotech,
Buckinghamshire, England).
Treatment of cultured fibroblasts with rottlerin. Rottlerin
was purchased from Biomol Research Laboratories Inc.
(Plymouth Meeting, Pennsylvania, USA). All other
chemicals were of reagent grade. Four strains of SSc
fibroblasts and two strains of normal fibroblasts were
studied. The cells were plated in 60-mm Falcon plastic
culture dishes (Becton Dickinson and Co., Lincoln Park,
New Jersey, USA) at a density of 150,000 cells per dish,
and cultured until confluent. For dose-response stud-
ies, the cells were incubated with 0.5–3.0 µM rottlerin in
1% FBS for 24 hours. All subsequent experiments were
performed with 3 µM rottlerin, a dose found to have the
maximum inhibitory effect on collagen gene expression.
Fibroblast collagen biosynthesis. Confluent fibroblast cul-
tures were used to examine the effects of rottlerin on
optimal fibroblast collagen biosynthesis as described
previously (23, 24). The medium was removed and 1.5
ml of fresh DMEM containing 3 µM rottlerin, 10% FBS,
50 µg/ml ascorbic acid, 100 µg/ml β-aminoproprioni-
trile, and 5 µCi/ml [14C]proline (specific activity: 247
mCi/mM; NEN Life Science Products, Boston, Massa-
chusetts, USA) was added. At various intervals after
incubation with [14C]proline, the medium was removed
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and the following reagents were added, to the indicated
final concentrations: 0.15 M NaCl, 0.05 M Tris-HCl, 4
mM EDTA, and 10 µg/ml PMSF. The samples were
then dialyzed against 0.15 M NaCl, 0.05 M Tris-HCl, pH
7.4 buffer containing the same concentration of pro-
tease inhibitors. The monolayers containing cells and
adherent protein were solubilized in 1 M NaCl, 0.05 M
Tris-HCl, pH 7.4 buffer containing 4 mM EDTA and 10
µg/ml PMSF, and the solutions were dialyzed as
described for the media. The amount of radiolabeled
(newly synthesized) collagen was measured by a colla-
genase digestion assay (25) using pure bacterial collage-
nase (BRL Laboratories Inc., Bethesda, Maryland, USA)
in the presence of protease inhibitors. In certain exper-
iments, both media and cell layers were analyzed. How-
ever, in most experiments, only the culture media were
studied, because as shown previously, more than 85% of
the total collagen synthesized by both the control and
the experimental cultures was released into the media
under the conditions used (23, 24).
Determination of type I collagen production. The type I
collagen present in culture media was quantified by an
indirect ELISA (26) using a human collagen type I poly-
clonal antibody (BIODESIGN International, Kenneb-
unk, Maine, USA). A standard curve was established
relating the inhibition of color development to the con-
centration of added antigen (human type I collagen;
Southern Biotechnology Associates, Birmingham,
Alabama, USA). The concentration of type I collagen in
the cell culture supernatants was analyzed in duplicate
and was determined directly from the standard inhibi-
tion curve, which was linear between 4 and 250 ng/ml
of type I collagen. The interassay variation was 10–15%,
and the intra-assay variation was 5–10%.
Northern hybridizations. Fibroblasts were grown to con-
fluence. Following incubation either under control con-
ditions or with rottlerin, total RNA was isolated by acid
guanidinium thiocyanate–phenol-chloroform extrac-
tion (27). Aliquots of total RNA (5–10 µg/well) were
electrophoresed on formaldehyde 1.2% agarose gels. The
RNA was then transferred to Zeta-Probe membranes
(Bio-Rad Laboratories Inc., Richmond, Virginia, USA)
by vacuum blotting, and the filters were hybridized to
32P-radiolabeled human cDNA for COL1A1, COL3A1,
and cyclooxygenase-1 as described previously (19).
Equivalent amounts of RNA were loaded, and RNA
loading and transfer were evaluated by probing with a
GAPDH cDNA. Equivalent loading and transfer were
also verified by quantitative image analysis of ethidium
bromide staining of ribosomal RNA in the same blots.
The filters were analyzed using phosphor imaging
eqiuipment (ImageQuant version 5.1 software, Molec-
ular Dynamics, Sunnyvale, California, USA). All mRNA
analyses were performed in duplicate.
In vitro nuclear transcription assay. The transcription
rates of COL1A1 and COL1A3 were measured by an in
vitro nuclear run-off assay. Fibroblasts were cultured in
T-175 flasks for 24 hours in the presence or absence of
3 µM rottlerin. At the end of the incubation period, cell
layers were trypsinized, nuclei were isolated, and tran-
scription reactions were carried out exactly as described
previously (28), except that after hybridizations the fil-
ters were analyzed using storage phosphor technology
(ImageQuant version 5.1 software).
Transient transfections of normal and SSc fibroblasts. Tran-
sient transfections and cotransfections of normal and
SSc fibroblasts were performed using the lipid-based Fu
Gene 6 Kit (Roche Diagnostic Corp., Indianapolis, Indi-
ana, USA) as described previously (29). Normal and SSc
fibroblasts were plated at 70% confluence in 60-mm
dishes. The medium was changed the next day, and 3
hours later the cells were transfected with a total of 2.5
µg of each plasmid. COL1A1 transcription was assessed
using several deletion constructs of the COL1A1 pro-
moter fused to the chloramphenicol acetyl transferase
reporter gene (CAT). All the constructs used end at
nucleotide +42 to assure transcription in a proper read-
ing frame; their 5′ ends are at –804, –675, –174, and –84
bp. The detailed procedures for preparation of these
constructs have been described previously (30, 31).
Cotransfections with constructs expressing wild-type
PKC-δ or a dominant-negative form of the enzyme (32)
were performed using 0.4 µg of either bp –804 or bp
–675 COL1A1-CAT constructs, and 0.4 µg of either of
the cotransfected PKC-δ constructs. Following transfec-
tions, fresh medium with or without rottlerin was added;
the cells were harvested 48 hours after transfection and
lysed by sonication. Total protein content of the cyto-
plasmic extracts was measured by the Bradford proce-
dure (33). CAT activity in cell extracts was determined by
TLC (34). The efficiency of transfection was normalized
by cotransfecting 2 µg of vector containing E. coli β-galac-
tosidase cDNA (pCMVβ-galactosidase; CLONTECH
Laboratories, Palo Alto, California, USA) followed by
assays of β-galactosidase enzymatic activity.
Cloning of the rottlerin-responsive element (RRE) upstream
of a thymidine kinase heterologous promoter. The construct
SJRott804 was generated by PCR amplification of the
region of the human COL1A1 promoter encompassing
nucleotides –675 to –804. This region was cloned into
pCRII (Invitrogen Corp., San Diego, California, USA),
and XbaI fragments were cloned immediately upstream
of the herpes simplex virus thymidine kinase (TK) pro-
moter of pBLCAT2 (CAT2), as described previously
(35). The plasmid SJRott804 was sequenced to confirm
its sequence and orientation relative to the TK pro-
moter. The construct was transfected into one line of
SSc cells, and following transfection the cells were
treated with 3 µM rottlerin as described above. CAT
activity was determined as described above.
Results
Effects of rottlerin on collagen production and biosynthesis in
normal and SSc dermal fibroblasts. To determine the effect
of inhibition of PKC-δ on the production of type I col-
lagen by normal and SSc fibroblasts, replicate conflu-
ent cultures of normal and SSc fibroblasts were 
incubated with 0.5–3.0 µM rottlerin, after which the col-
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lagen secreted into the culture media was analyzed by a
specific ELISA. Rottlerin decreased the production of
type I collagen by both normal and SSc fibroblasts in a
concentration-dependent manner, so that at 3 µM there
was approximately 90% inhibition (Figure 1a). Biosyn-
thetic studies demonstrated that rottlerin caused a pro-
found reduction in the amounts of newly synthesized
collagen (Figure 1b). The amount of radiolabeled colla-
genase-sensitive protein, representing newly synthesized
collagen, was nearly fourfold greater in SSc cells than in
normal cells (7,005 cpm vs. 1,974 cpm, respectively).
Rottlerin at the optimal concentration (3 µM) reduced
newly synthesized collagen by about 90% in the SSc
cells, and by about 70% in normal cells.
Effects of rottlerin on type I and type III collagen gene expres-
sion in normal and SSc cells. Total RNA from normal and
SSc cells cultured under control conditions or in the
presence of increasing concentrations of rottlerin was
analyzed by Northern hybridizations for COL1A1 tran-
scripts. SSc cells contained greater levels of COL1A1
mRNA than normal cells; rottlerin caused a concentra-
tion-dependent reduction in these levels, with a reduc-
tion of approximately 70–90% at a 3-µM concentration
in both normal and SSc fibroblasts (Figure 2).
To examine the consistency of rottlerin effects, sever-
al normal and SSc fibroblast cell line cultures were
incubated with 3 µM rottlerin, and COL1A1 expression
was examined. Rottlerin uniformly caused a marked
decrease of COL1A1 expression in the two normal and
four SSc cell lines tested. At the protein level, collagen
production was inhibited by 90% in the normal cells,
and by 73–86% in the SSc cells (Figure 3a). Northern
hybridizations confirmed the inhibitory effect; the
steady-state α1(I) collagen mRNA levels were reduced
by 88% and 98% in the two normal cell lines, and by
83–99% in the four SSc cell lines (Figure 3b). The effects
of 3 µM rottlerin on mRNA levels of COL3A1 were also
examined in the four SSc cell lines, and inhibition rang-
ing from 66% to 85% was found (Figure 4).
To determine whether the effects of rottlerin on the
expression of collagen genes were selective, mRNA lev-
els for cyclooxygenase-1, a constitutively expressed gene,
were also examined. Rottlerin did not cause appreciable
changes in cyclooxygenase-1 transcripts in any of the
normal (not shown) or SSc cells (Figure 5) examined.
Furthermore, the levels of GAPDH were not affected by
rottlerin in either normal or SSc cells (Figures 2–5).
Effect of rottlerin on COL1A1 transcription. SSc fibrob-
lasts obtained from two different individuals (S1 and
S2) were treated with 3 µM rottlerin. Subsequently,
their nuclei were isolated and used for assessment of
the rates of transcription of types I and III collagen
genes. The results (Figure 6) showed that the tran-
scription of COL1A1 was decreased by 70% in cell line
S1, and by 53% in cell line S2. Transcription of COL3A1
was inhibited by more than 95% in both cell lines. In
contrast, the transcription of the GAPDH gene was
only minimally affected.
Identification of the COL1A1 promoter region responsive to
rottlerin. To identify the region of the COL1A1 promot-
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Figure 1
Effect of inhibition of PKC-δ by rottlerin on type I collagen produc-
tion and biosynthesis. (a) Confluent cultures of normal (open
squares) and SSc (filled squares) dermal fibroblasts were incubated
for 24 hours with the indicated concentrations of rottlerin, as
described in Methods. The culture media were analyzed for type col-
lagen I using specific ELISA. Values represent the average of duplicate
cultures determined in duplicate. (b) Confluent cultures of normal
(diamonds) and SSc (squares) dermal fibroblasts were incubated
under control conditions (open symbols) or with 3 µM rottlerin
(filled symbols) and labeled with [14C]proline, as described in Meth-
ods. Two plates from each set were harvested 8 hours and 16 hours
after labeling, and the amount of radiolabeled collagen representing
newly synthesized protein present in the media was determined by a
collagenase digestion assay.
Figure 2
Effects of inhibition of PKC-δ on type I collagen mRNA steady-state
levels. Total RNA prepared from normal (filled squares) or SSc (open
squares) cells treated with various concentrations of rottlerin for 24
hours was subjected to Northern hybridization analysis using
COL1A1 cDNA as described in Methods. The two COL1A1 tran-
scripts are indicated by arrowheads. The Northern blots were ana-
lyzed by phosphor storage technology; the values shown represent
percentage of control (untreated) values.
er that is responsive to rottlerin effects, untreated and
rottlerin-treated SSc fibroblasts were transiently trans-
fected with gene constructs containing various dele-
tions of the COL1A1 promoter ligated to the CAT
reporter gene. The results (Figure 7a) demonstrated that
the promoter activity of bp –174 or bp –675 constructs
was not affected, whereas that of the bp –804 construct
was decreased by more than 85% following treatment
with rottlerin. These results indicated that the inhibito-
ry effect of rottlerin on COL1A1 promoter transcrip-
tional activity was exerted through the 129-bp promot-
er region encompassing nucleotides –675 to –804.
To confirm that the COL1A1 promoter region from
bp –675 to –804 was necessary and sufficient for rott-
lerin-inducible effects on transcription of the gene, the
fragment of the COL1A1 promoter encompassing the
putative rottlerin-responsive region was subcloned
upstream of the herpes simplex virus TK promoter–CAT
transcription unit, and was transfected into SSc cells.
The results (Figure 7b) demonstrated that rottlerin
caused a 75% reduction in CAT activity, driven by the
heterologous TK promoter when the COL1A1 promot-
er segment encompassing nucleotides –675 to –804 was
cloned upstream of the TK promoter.
Inhibition of COL1A1 transcription by dominant-negative
PKC-δ expression. To provide independent evidence for
the role of PKC-δ in the regulation of collagen gene
expression, normal and SSc cells were cotransfected
with COL1A1 promoter constructs and with expres-
sion constructs coding for wild-type or dominant-neg-
ative PKC-δ (32). The results demonstrated that com-
pared with the wild-type PKC-δ, the dominant-negative
PKC-δ inhibited the promoter activity of the bp –804
construct in both the normal (40% inhibition) and SSc
cells (54% inhibition) (Figure 8). Significantly, the pro-
moter activity of the bp –675 construct was unaffected
by expression of dominant-negative PKC-δ.
PKC-δ expression in cultured normal and SSc fibroblasts.
The above findings suggested that increased expression
of PKC-δ may play an important role in stimulating
collagen production in SSc cells. Therefore, the levels
of PKC-δ in normal and SSc cells were compared by
high-resolution immunomicroscopy and Western
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Figure 3
Effects of rottlerin on type I collagen production and COL1A1 steady-
state mRNA levels by several cell lines of normal and SSc dermal fibrob-
lasts. (a) Confluent cultures of normal (N) and SSc (S) dermal fibrob-
lasts were incubated for 24 hours with or without 3 µM rottlerin, and
type I collagen secreted into the media was determined by specific
ELISA. Values represent the average of duplicate cultures determined in
duplicate. (b) Confluent cultures of normal (N) and SSc (S) dermal
fibroblasts were incubated for 24 hours with or without 3 µM rottlerin,
and the levels of COL1A1 mRNA were determined by Northern
hybridization analysis. The two COL1A1 transcripts are indicated by
arrowheads. Phosphor image analysis of the Northern blots is shown in
actual pixel density after correction for the values obtained with GAPDH
hybridizations. Values represent the average of duplicate cultures.
Figure 4
Effect of rottlerin on COL3A1 mRNA levels in SSc dermal fibroblasts.
Confluent cultures of SSc fibroblasts (S1–S4) were incubated for 24
hours with or without 3 µM rottlerin, and the levels of COL3A1
mRNA were determined by Northern hybridization analysis. The two
COL3A1 transcripts are indicated by arrowheads. Densitometric
analysis of the Northern blots is shown in actual pixel density after
correction for the values obtained with GAPDH hybridizations. Val-
ues represent the average of duplicate cultures.
analysis. The apparent level of expression of PKC-δ epi-
topes was greater in SSc cells than in normal cells, as
observed by high-resolution immunofluorescence
microscopy (Figure 9). Western analyses also showed
significantly higher PKC-δ immunoreactivity in cell
lysates from three SSc cell isolates than in those from
three normal controls (Figure 10).
Discussion
Tissue fibrosis is the hallmark of numerous human dis-
eases such as scleroderma, pulmonary fibrosis, liver cir-
rhosis, and graft-versus-host disease, among others.
The most prominent biochemical manifestation of
these fibrotic processes, also known as fibroprolifera-
tive diseases, is an abnormal and exaggerated accumu-
lation of extracellular matrix macromolecules, in par-
ticular of type I and type III interstitial collagens.
The mechanisms involved in the regulation of
expression of the genes encoding the interstitial colla-
gens under physiologic conditions or during normal
tissue repair have not been completely elucidated.
Even more elusive have been the pathogenetic steps
that lead to increased expression of these genes in
abnormal fibrogenesis, such as that occurring in the
fibroproliferative diseases. Numerous studies have
implicated members of the TGF-β family of proteins
as playing a crucial role in the initiation and progres-
sion of pathologic fibrogenesis (reviewed in refs. 11,
12). The TGF-β proteins are pleiotropic in their bio-
logical activities, modulating cell growth and differ-
entiation as well as extracellular matrix deposition and
degradation. This wide range of activities is initiated
following interactions of the active TGF-β proteins
with specific transmembrane receptors, which posses
both constitutive (type II) and activated (type I) serine-
threonine kinase activity (reviewed in refs. 14, 15, 36).
Although the varied biological activities of the 
TGF-βs have been well documented, the mechanisms
through which these molecules modulate the expres-
sion of the numerous target genes have been only par-
tially elucidated. Of particular importance are the
intracellular transduction pathways that transmit cell-
surface signals to the transcriptional units of specific
genes, and how these signals provide the selectivity
required to influence only certain genes under given
conditions. Since the TGF-β family is involved in the
regulation of a wide variety of fundamental cell
processes, it is to be expected that the signaling mech-
anisms by which these effects are achieved are complex.
The discovery that Smad proteins are key intermediates
in the signaling process linking TGF-β receptors to cel-
lular responses has revealed important new informa-
tion on the way cells respond to this cytokine (reviewed
in refs. 14, 15). These studies have established a basic
framework upon which a comprehensive under-
standing of the molecular events required for 
TGF-β–induced modulation of gene expression can be
constructed. However, current understanding of these
pathways is far from complete.
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Figure 5
Effect of rottlerin on cyclooxygenase-1 expression. Confluent cultures
of SSc dermal fibroblasts (S1–S4) were incubated for 24 hours with
or without 3 µM rottlerin, and cyclooxygenase-1 and GAPDH levels
were determined by Northern hybridizations as described in Meth-
ods. Phosphor image analysis of the Northern blots is shown in actu-
al pixel density after correction for the values obtained with GAPDH
hybridization. Values represent the average of duplicate cultures.
COX-1, cyclooxygenase-1.
Figure 6
In vitro nuclear transcription of control or rottlerin-treated SSc cells.
Confluent cultures of SSc fibroblasts (S1, S2) were incubated in T-175
flasks in MEM supplemented with 10% (vol/vol) FBS and ascorbic acid
(50 µg/ml) with or without rottlerin (3 µM) for 24 hours. Nuclei were
prepared and in vitro transcription assays were performed as described
in Methods. Aliquots of 32P-labeled RNA containing equal cpm were
hybridized to duplicate dot-blotted cDNAs for α1(I) and α1(III) pro-
collagens, GAPDH, or the plasmid pUC19. After hybridization these
were analyzed using storage phosphor technology. The values obtained
were corrected for the transcription of GAPDH after subtraction of the
background represented by pUC19. The values shown represent the
corrected pixel densities from the average of two separate experiments.
We have recently undertaken studies to identify non-
Smad pathways that may participate in the regulation
of expression of genes that encode various extracellu-
lar matrix proteins by members of the TGF-β family.
We identified the following enzymes as possible com-
ponents in the overall regulation of fibronectin, type I
and III collagens, and elastin by TGF-β1: phos-
phatidylcholine-specific phospholipase C, PKC-δ, and
geranylgeranyl transferase I (16–18). While these reac-
tions are best known for their potential roles in medi-
ating cytokine and growth factor signal transduction,
we postulate that they may also be involved in regulat-
ing the levels of constitutive expression of matrix genes,
including type I and type III collagens, and that altered
activity of one or more of these components may play
an important role in the pathogenesis of SSc and other
fibroproliferative diseases. In order to test this hypoth-
esis, we are investigating the effect of modulating the
intracellular activity of each of these enzymes on the
constitutive expression of matrix protein genes in nor-
mal and SSc cells. In a recent study, we demonstrated
that inhibition of prenylation catalyzed by geranylger-
anyl transferase I resulted in profound and selective
inhibition of the expression of types I and III collagen
genes (19). We further demonstrated that these
inhibitory effects were largely due to a reduction in the
transcription rate of the type I procollagen gene (19).
The PKC family of proteins is comprised of at least
ten isozymes with diverse functions that are involved in
numerous important cellular processes. These proteins
have been divided into three groups based on their
structure, cofactor requirements, and cellular distribu-
tion (reviewed in refs. 37–39). Numerous studies have
established that PKC activation is necessary for stimu-
lation of gene expression in response to proinflamma-
tory cytokines, such as IL-1 and TNFs (40, 41), and that
these effects appear to be mediated by specific activa-
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Figure 7
Identification of the COL1A1 promoter region responsive to rottlerin.
(a) Autoradiogram of CAT assays performed with extracts from SSc
cells that had been transfected with 2.5 µg of one of various deletion
constructs of COL1A1 with 5′ endpoints at –804, –675, and –174,
and then incubated with 3 µM rottlerin for 24 hours. The bar graph
shows the densitometric scanning of the autoradiograms; the bars
indicate arbitrary densitometric units of acetylated chloramphenicol.
(b) Autoradiogram of CAT assays performed with extracts from SSc
cells that had been transfected with 2.0 µg of SJRott804 containing
nucleotides –675 to –804 of the COL1A1 promoter, cloned upstream
of the heterologous herpes simplex virus TK promoter and treated
with or without 3 µM rottlerin for 24 hours after transfection. The bar
graph shows the densitometric analysis of the autoradiograph show-
ing the proportion of acetylated chloramphenicol. CAT2, pBL CAT2;
CAT2-RRE, pBLL CAT2 with rottlerin response element.
Figure 8
Cotransfection of COL1A1 promoter constructs and PKC-δ expression
constructs into normal and SSc fibroblasts. Normal and SSc fibrob-
lasts were cultured to 70% confluence and then cotransfected with 0.4
µg of either bp –675 or bp –804 COL1A1 deletion constructs and 0.4
µg of either a wild-type or a dominant-negative PKC-δ expression con-
struct, as described in Methods. Following transfections, cell extracts
were assayed for CAT activity. The upper panels show the autoradi-
ograms of the CAT assays. The lower panels show the quantitation of
CAT activity following normalization for the activity of the cotrans-
fected β-galactosidase gene. Note that expression of the dominant-
negative PKC-δ construct decreases the transcriptional activity of the
bp –804 COL1A1 construct, but has no effect on that driven by the bp
–675 COL1A1 construct. WT, wild-type; DN, dominant negative.
tion of a variety of transcription factors, including 
AP-1 (42), ATF-2 (43), and NF-κB (44, 45). However, a
role for these enzymes in the regulation of collagen
gene expression has not been described previously, nor
have their effects on transcription factors involved in
stimulating the transcriptional activity of collagen
genes such as Sp1 or CCAAT binding factor.
Here, we examined the possibility that PKC-δ may be
involved in the upregulation of collagen gene expression
in SSc by assessing the levels of PKC-δ in normal and
SSc cells using high-resolution fluorescence immu-
nomicroscopy and Western analyses of cell lysates. We
also analyzed the effects of expression of a dominant-
negative PKC-δ construct on the promoter activity of
COL1A1. In addition, we examined the effects of the
selective inhibition of this PKC isozyme on collagen
gene expression in these cells. For the latter purpose, we
used rottlerin, a compound shown previously to cause
a potent inhibition of PKC-δ at concentrations that do
not affect other PKCs (20, 21). The IC50 for PKC-δ is 3–6
µM, whereas all other PKCs are not inhibited until con-
centrations become at least one order of magnitude
higher (20). The results demonstrated that SSc cells
contained higher levels of immunoreactive PKC-δ than
do normal cells. Furthermore, expression of a domi-
nant-negative PKC-δ construct resulted in a substantial
reduction in the promoter activity of COL1A1. The
results using rottlerin showed that at low concentra-
tions (3 µM), it caused a potent inhibition of COL1A1
and COL1A3 expression in both cell types. In contrast,
expression of the constitutively expressed cyclooxyge-
nase-1 and GAPDH genes was not affected, indicating
that the inhibition was not due to a generalized toxic
effect. In addition, there was no obvious cytotoxicity, as
determined by trypan blue exclusion.
Our previous finding that inhibition of geranylger-
anyl transferase I markedly reduced expression of types
I and III collagens by normal and SSc fibroblasts sug-
gested that a small prenylated GTPase belonging to the
Ras superfamily may be involved in the regulation of
collagen gene expression (19). Our current finding that
inhibition of PKC-δ also resulted in a profound decrease
in expression of type I and type III collagen raises the
intriguing possibility that there may be a direct rela-
tionship between the activity of a small GTPase and
PKC activation. Indeed, such a relationship has been
proposed by Kamada et al. in a yeast system (46). Also,
Hippensteil et al. have shown that inactivation of Rho,
but not Ras proteins, prevented the translocation and
activation of PKC-α in human endothelial and
bronchial epithelial cells (47). These results support the
notion that inhibition of geranylgeranyl transferase I
might block the activation of PKC-δ.
In the present study, we further demonstrated that
rottlerin acts ultimately at the transcriptional level, and
that its effect on COL1A1 expression is mediated
through a 129-bp gene promoter segment encompass-
ing nucleotides –675 to –804. The critical role of this
region was supported by the finding that expression of
dominant-negative PKC-δ inhibited the promoter
activity of the bp –804 construct, but not that driven by
the bp –675 construct. This region of the COL1A1 pro-
moter does not contain regulatory elements that were
previously considered to be involved in the transcrip-
tional regulation of the gene. Thus, it is very likely that
the rottlerin response is mediated by COL1A1 pro-
moter elements not previously recognized as partici-
pants in the upregulation of collagen gene expression
in SSc cells. Identification of these elements, which is
currently in progress, could shed light on critical mech-
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Figure 9
High-resolution fluorescence immunomi-
croscopy of normal and SSc fibroblasts with
an anti–PKC-δ antibody. Normal and SSc
fibroblasts were cultured on coverslips, and
when confluent were processed for high-res-
olution fluorescence immunomicroscopy
using a polyclonal anti–PKC-δ antibody as
described in Methods. (a) Normal fibrob-
lasts. (b) SSc fibroblasts. Note the higher
immunofluorescence displayed by SSc
fibroblasts in comparison with normal cells.
Figure 10
Western analysis of cell lysates from normal and SSc fibroblasts with
an anti–PKC-δ antibody. Three cell lines of either normal or SSc der-
mal fibroblasts were cultured until confluent, and whole cell lysates
were prepared as described in Methods. Aliquots of the lysates from
each cell line were submitted to Western analysis using a polyclonal
anti–PKC-δ antibody. Note that the main immunoreactive protein
band (identified with the arrowhead) corresponding to PKC-δ is sub-
stantially increased in SSc fibroblasts compared with normal cells.
anisms regulating interstitial collagen gene expression,
both under normal conditions and in the course of
fibroproliferative diseases. Our results also suggest that
PKC-δ may be involved in the pathogenesis of the dys-
regulation of collagen gene expression that is charac-
teristic of SSc. Further clarification of the putative role
of PKC-δ in this process could provide valuable clues
for the development of novel strategies for the treat-
ment of deleterious fibrotic reactions, including those
occurring in SSc.
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